Mani Foroohar
Stock Analyst at Leerink Partners
(0.11)
# 4,800
Out of 5,128 analysts
948
Total ratings
43.4%
Success rate
-7.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mani Foroohar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCKT Rocket Pharmaceuticals | Reiterated: Hold | $4 | $2.39 | +67.36% | 58 | Nov 13, 2026 | |
| ENGN enGene Therapeutics | Reiterated: Hold | $2 | $2.28 | -12.28% | 14 | Sep 9, 2026 | |
| ABSI Absci | Initiated Coverage: Buy | $12 | $9.14 | +31.36% | 1 | Jun 4, 2026 | |
| MIRM Mirum Pharmaceuticals | Reiterated: Buy | $100 → $154 | $93.33 | +65.01% | 54 | May 15, 2026 | |
| RGNX REGENXBIO | Reiterated: Buy | $17 | $8.03 | +111.71% | 64 | May 15, 2026 | |
| NTLA Intellia Therapeutics | Reiterated: Buy | $27 → $35 | $10.55 | +231.75% | 52 | Apr 27, 2026 | |
| CAMP Camp4 Therapeutics | Reiterated: Buy | $8 → $9 | $4.09 | +120.05% | 7 | Apr 2, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Reiterated: Hold | n/a | $47.15 | - | 56 | Mar 26, 2026 | |
| MRNA Moderna | Reiterated: Sell | $12 | $231.35 | -94.81% | 89 | Feb 11, 2026 | |
| ALNY Alnylam Pharmaceuticals | Reiterated: Hold | $370 → $351 | $156.65 | +124.07% | 67 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $370 → $86 | $78.17 | +10.02% | 76 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $68 → $100 | $27.31 | +266.17% | 67 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $3 → $2 | $0.3475 | +475.54% | 16 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 → $18 | $2.91 | n/a | 16 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $56 → $74 | $42.62 | n/a | 27 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $12.12 | n/a | 41 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $3.33 | n/a | 34 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $51 → $48 | $43.16 | n/a | 2 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $9.09 | n/a | 9 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $24.03 | n/a | 20 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $32 → $27 | $30.85 | n/a | 12 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $3 | $0.3802 | n/a | 32 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 | $23.90 | n/a | 13 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1 | $2.14 | n/a | 20 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1 | $1.66 | n/a | 31 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $8.60 | n/a | 3 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $21 | $4.09 | n/a | 15 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | n/a | $15.23 | n/a | 1 | Jun 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $6 → $5 | $3.16 | n/a | 24 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $5 → $6 | $2.29 | n/a | 17 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $21.04 | n/a | 7 | Oct 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $216 → $197 | $16.01 | n/a | 3 | Nov 6, 2020 |
Rocket Pharmaceuticals
Nov 13, 2026
Reiterated: Hold
Price Target: $4
Current: $2.39
Upside: +67.36%
enGene Therapeutics
Sep 9, 2026
Reiterated: Hold
Price Target: $2
Current: $2.28
Upside: -12.28%
Absci
Jun 4, 2026
Initiated Coverage: Buy
Price Target: $12
Current: $9.14
Upside: +31.36%
Mirum Pharmaceuticals
May 15, 2026
Reiterated: Buy
Price Target: $100 → $154
Current: $93.33
Upside: +65.01%
REGENXBIO
May 15, 2026
Reiterated: Buy
Price Target: $17
Current: $8.03
Upside: +111.71%
Intellia Therapeutics
Apr 27, 2026
Reiterated: Buy
Price Target: $27 → $35
Current: $10.55
Upside: +231.75%
Camp4 Therapeutics
Apr 2, 2026
Reiterated: Buy
Price Target: $8 → $9
Current: $4.09
Upside: +120.05%
Arrowhead Pharmaceuticals
Mar 26, 2026
Reiterated: Hold
Price Target: n/a
Current: $47.15
Upside: -
Moderna
Feb 11, 2026
Reiterated: Sell
Price Target: $12
Current: $231.35
Upside: -94.81%
Alnylam Pharmaceuticals
Dec 15, 2025
Reiterated: Hold
Price Target: $370 → $351
Current: $156.65
Upside: +124.07%
Dec 15, 2025
Reiterated: Buy
Price Target: $370 → $86
Current: $78.17
Upside: +10.02%
Dec 15, 2025
Reiterated: Buy
Price Target: $68 → $100
Current: $27.31
Upside: +266.17%
Dec 15, 2025
Reiterated: Buy
Price Target: $3 → $2
Current: $0.3475
Upside: +475.54%
Oct 21, 2025
Reiterated: Buy
Price Target: $20 → $18
Current: $2.91
Upside: n/a
Oct 15, 2025
Reiterated: Buy
Price Target: $56 → $74
Current: $42.62
Upside: n/a
Oct 15, 2025
Reiterated: Buy
Price Target: n/a
Current: $12.12
Upside: n/a
Oct 15, 2025
Reiterated: Hold
Price Target: n/a
Current: $3.33
Upside: n/a
Sep 25, 2025
Reiterated: Buy
Price Target: $51 → $48
Current: $43.16
Upside: n/a
Sep 23, 2025
Reiterated: Buy
Price Target: $20
Current: $9.09
Upside: n/a
Sep 3, 2025
Reiterated: Buy
Price Target: n/a
Current: $24.03
Upside: n/a
Aug 18, 2025
Reiterated: Buy
Price Target: $32 → $27
Current: $30.85
Upside: n/a
Aug 13, 2025
Reiterated: Buy
Price Target: $3
Current: $0.3802
Upside: n/a
Aug 12, 2025
Reiterated: Buy
Price Target: $70
Current: $23.90
Upside: n/a
Mar 6, 2025
Reiterated: Hold
Price Target: $1
Current: $2.14
Upside: n/a
Aug 9, 2024
Reiterated: Hold
Price Target: $1
Current: $1.66
Upside: n/a
Jul 15, 2024
Reiterated: Buy
Price Target: n/a
Current: $8.60
Upside: n/a
Nov 13, 2023
Reiterated: Hold
Price Target: $21
Current: $4.09
Upside: n/a
Jun 8, 2023
Reiterated: Sell
Price Target: n/a
Current: $15.23
Upside: n/a
May 23, 2023
Reiterated: Hold
Price Target: $6 → $5
Current: $3.16
Upside: n/a
Nov 14, 2022
Reiterated: Hold
Price Target: $5 → $6
Current: $2.29
Upside: n/a
Oct 19, 2021
Reiterated: Hold
Price Target: n/a
Current: $21.04
Upside: n/a
Nov 6, 2020
Reiterated: Buy
Price Target: $216 → $197
Current: $16.01
Upside: n/a